Key result
Ischemic heart disease is linked to significantly elevated levels of IL-6, sIL-6R, and TNF-α.
Why the study?
Immunological mediators play a role in the development and pathogenesis of ischemic heart disease, warranting evaluation of IL-6, TNF-alpha, and IL-6 receptor changes in these patients.
Are serum levels of IL-6, TNF-α, and sIL-6R elevated in patients with ischemic heart disease compared to healthy controls?
Case-Control (n=90)
Are serum levels of IL-6, TNF-α, and sIL-6R elevated in patients with ischemic heart disease compared to healthy controls?
Increased concentrations of inflammatory markers IL-6, sIL-6R, and TNF-α are associated with ischemic heart disease, suggesting a role in coronary endothelial dysfunction.
Answers are grounded in this paper and cite their sources.
Supports a role for systemic inflammation in ischemic heart disease; leaves open whether targeting these specific cytokine pathways improves.
Background: Ischemic heart disease (IHD) presents a significant burden on individuals and healthcare systems globally. The prevalence of risk factors, along with an aging population, continues its status as the leading cause of death worldwide. Immunological mediators play a clear role in the development of heart disease, as some studies have indicated their importance in the pathogenesis of IHD. Objectives: This article aimed to evaluate the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and the changes in IL-6 receptor in IHD patients. Materials and Methods: A total of 90 samples, including 60 from IHD patients aged 40–85 years, and 30 randomly selected controls with matching age range. Serum levels of TNF-α, IL-6, and human soluble IL-6 receptor (sIL-6R) were measured using the enzyme-linked immunosorbent assay method, which was estimated according to the manual procedure of Bioassay Technology Laboratory kit from China. Results: In the IHD group, IL-6 and sIL-6R levels were markedly elevated compared to control subjects. In addition, TNF-α showed a significant increase ( P < 0.05) in IHD patients compared to healthy subjects. Based on blood pressure (BP) groups, IL-6 showed a significant difference ( P < 0.05) when compared between Group 2 (elevated BP) and Group 4 [hypertension (HT) stage II], with P value of 0.03. While the serum level of TNF-α in Group 3 (HT stage I) showed a significant difference compared to Group 1: Normal BP, Group 2: Elevated BP, and Group 4: HT stage II, with a P value ≤ 0.01. Conclusion: Increased concentrations of IL-6, sIL-6R, and TNF-α might have a crucial contribution to coronary endothelial dysfunction in IHD patients.
No takes yet. Share an insight, caveat, or question.
Almadany et al. (2026) conducted a case-control in Ischemic heart disease (n=90). Ischemic heart disease vs. Healthy age-matched controls was evaluated on Serum levels of IL-6, sIL-6R, and TNF-α (p=<0.05). Ischemic heart disease was associated with elevated serum levels of IL-6, sIL-6R, and TNF-α compared to healthy age-matched controls.
Synapse has enriched 10 related papers. Consider them for comparative context: